NCT04907019已完成1 期
A Single Center, Open-label, Single Sequence Study to Evaluate the Potential Drug Interaction of CYP3A4 Inducer Rifampicin With SY-004 Capsules in Healthy Subjects
Suzhou Yabao Pharmaceutical R&D Co., Ltd.1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2021年7月6日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
A single center, open-label, single sequence study was conducted to evaluate the potential drug interaction of CYP3A4 inducer rifampicin with SY-004 capsules in healthy subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subjects can communicate well with the researchers, understand and comply with the requirements of this study, and sign the informed consent voluntarily.
- •Age on the day of signing the informed consent: healthy subjects aged 18 or above, both male and female.
- •At the time of screening, male weight ≥ 50.0 kg, female weight ≥ 45.0 kg, 19.0 kg / m2 ≤ BMI ≤ 26.0 kg / m
- •Fasting blood glucose ≥ 3.9 mmol / L and < 6.1 mmol / L.
- •From one month before the informed consent to three months after the last medication, the subjects and their partners had no plans to have a child, take effective contraceptive measures voluntarily, and donate sperm or eggs.
排除标准
- •Within 3 months before screening, a clinical trial was completed or withdrawn, or a clinical trial was in progress, or participated in other medical trial activities, and the researcher judged that it was not suitable to participate in this trial.
- •With a history of serious systemic diseases or family history (including cardiovascular system, digestive system, urinary system, etc.), the researchers judged that the disease status could significantly change the absorption, distribution, metabolism and excretion of experimental drugs, or taking experimental drugs would increase the risk of subjects.
- •Allergic constitution, or history of food allergy, or known allergy to study drug / similar drug, or to rifampicin or rifamycin antibiotics.
- •Patients with previous orthostatic hypotension.
- •Those who had a history of drug abuse, drug abuse or positive urine drug screening results in the past five years.
- •Those who donated blood or lost more than 400ml in 4 weeks before screening, or received transfusion of blood or blood components in 4 weeks before screening, or planned to donate blood components within 3 months after the end of the study.
- •Those who have a history of needle syncope or blood syncope, or who can't tolerate venipuncture for blood collection, or who have difficulty in blood collection.
- •The patients with severe infection, trauma or major surgery within 4 weeks before the screening, or who plan to perform surgery during the study period (including but not limited to dental surgery).
- •Use any prescription, over-the-counter, herbal or health products within 2 weeks before screening.
- •Any drugs that inhibit or induce liver drug metabolizing enzymes were used within 30 days before screening.
- •During the first three months of screening, the average alcohol intake was more than 14 units per week (1 unit = 360ml beer, 45ml spirits with 40% alcohol content or 150ml wine), or those who could not give up drinking during the test period, or those with positive alcohol breath.
- •Smoking more than 5 cigarettes per day within 3 months before screening, or unwilling / unable to give up smoking during the trial.
- •Those who have special requirements for diet and can not comply with the unified diet arrangement.
- •It is not guaranteed that chocolate, any food or drink containing caffeine or possibly affecting the test results (such as pitaya, grapefruit, grapefruit, orange juice, mango, etc.) will be fasted 48 hours before administration and during the test.
- •Pregnant or lactating women, or pregnancy test results were positive.
- •The screening results of HBsAg, HCV, TP and HIV were positive.
- •When screening, there was ALT > 1.5 times the upper limit of normal value（ × ULN), or ast > 1.5 × ULN, or TBIL > 1.5 × ULN。
- •When screening, the 12 lead ECG showed the following results: QT interval (qtcb) > 450ms (male) or > 470ms (female).
- •The results of physical examination, vital signs, abdominal B-ultrasound (liver, gallbladder, pancreas, spleen and kidney), chest CT, ECG, laboratory examination items and test related auxiliary examination in screening period were not suitable for the participants.
- •According to the judgment of the researcher, the subjects with other factors not suitable to participate in the experiment.
研究组 & 干预措施
Group-drugs interaction
Experimental
24 subjects were enrolled in this study. The effects of rifampicin single dose and steady-state on the pharmacokinetics of sy-004 will be analyzed.
干预措施: rifampicin，SY-004 (Drug)
结局指标
主要结局
Cmax
时间窗: 22 days
Peak Plasma Concentration (Cmax) of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level
AUC0-t
时间窗: 22 days
Area under the plasma concentration versus time curve (AUC0-t)) of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level
AUC0-∞
时间窗: 22 days
Area under the plasma concentration versus time curve (AUC0-∞)) of SY-004 when SY-004 capsules were treated with rifampicin alone or in combination with rifampicin at steady-state level
次要结局
- Tmax(22 days)
- T1/2z(22 days)
- CLz/F(22 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese VolunteersHealthy VolunteersHemophilia ANCT03380780Hoffmann-La Roche16
已完成
1 期
The Pharmacokinetics, Tolerability and Safety of Brexpiprazole in Healthy Chinese SubjectsHealthNCT03734354Otsuka Beijing Research Institute30
进行中（未招募）
2 期
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard TherapyColorectal CancerNCT05435313Fudan University39
尚未招募
不适用
Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic CholangiocarcinomaIntrahepatic CholangiocarcinomaNCT06313554Fudan University63
尚未招募
1 期
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerMetastatic Triple-negative Breast CancerNCT05746728Huihua Xiong45